e-Drug3D

1584

AVANAFIL

INN
AVANAFIL

cas 330784-47-9

CLASS

GENITO
PHOSPHODIESTERASE 5 (PDE5) INHIBITOR
TREATMENT OF ERECTILE DYSFUNCTION

ROUTE (list)

ORAL

ATC code

G04BE10

PK parameters

Tmax 0.62 HOUR
PPB 99 PERCENT
t1/2 5 HOUR

Solubility

PRACTICALLY INSOLUBLE IN WATER

Target

TARGET PHOSPHODIESTERASE 5 (PDE5)

PDB
6L6E (HUMAN PDE5 CATALYTIC CORE IN COMPLEX WITH AVANAFIL)

Ligand code = E6L (link to the list of PDB complexes)

Download experimental 3D coordinates of E6L with added hydrogens

DrugCentral

cGMP-specific 3,5-cyclic phosphodiesterase UNIPROT O76074 PDE5A

Download SDF file

5-Pyrimidinecarboxamide, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)-

Formula:
C23H26ClN7O3

Calculated chemical properties:

MW 483.96
NB_atoms 34
XLogP 2.43
PSA 110.051
NB_HD 3
NB_HA 10
fsp3 0.35
Lipinski(0=no;1=yes) 1

FDA
NDA 202276 (label) INN (AVANAFIL) STENDRA (VIVUS LLC) APPROVAL= AP YEAR= 2012
NDA 209266 (pdf not found) INN (AVANAFIL) AVANAFIL (HETERO LABS LTD V) APPROVAL= AP YEAR= 2024